Peptide Policy Watch

The glutathione injection recall: what FDA's October 1 notice says, and what it doesn't

By · Published

A home desk at dusk with a lit lamp, an open laptop with a dark screen, a notepad with a pen and a magnifying glass, and blue evening light at the window.

Picture a clinic menu with a glutathione injection on it, and a news alert on your phone: a pharmacy is recalling glutathione. Is that the same product? Is the whole category suspect? Or is it one pharmacy, a few lots and one specific problem?

Here's what the official notices say, and where they stop.

Not medical advice, and the site owner isn't a medical professional. Facts are as of October 25, 2026; sources and retrieval dates are at the bottom.

What happened

On October 1, 2026, FDA posted a recall announcement from Greenwich Rx, a compounding pharmacy in Tomball, Texas. The company calls itself a 503A pharmacy and says it is pulling named lots of its compounded glutathione off the market, for "potential elevated endotoxin levels" [V]. Endotoxins are substances some bacteria make, and CDC says they can contaminate medicines when quality controls slip [V]. FDA's page adds that it "does not endorse either the product or the company" [V].

  • 2reports of emergency-department care after intravenous use, per the company [V]
  • June 26 – Sept 21, 2026window when the recalled product was distributed nationwide [V]
  • 10 vs. 12lots listed in FDA's notice versus a California Board of Pharmacy copy [V]

The product is a multidose vial described as intended for injection under the skin. The company says two patients got emergency care after receiving it into a vein, which it says the product wasn't formulated for [V]. Its notice tells customers with a recalled lot to stop using it and follow the disposal instructions it mails out, and tells anyone who thinks they had a reaction to contact a health care provider [V].

The wider story behind it

It isn't a one-off. FDA's August 27, 2026 notice says it knew of at least 30 patients with adverse events after intravenous glutathione from several pharmacies, all using one lot of an ingredient labeled "dietary supplement grade," which FDA calls inappropriate for injectable drugs [V]. CDC's September 15 page counts more than 25 people ill in at least four states, at least three hospitalized, and says no glutathione product is FDA-approved in the U.S. [V] FDA's recall pages also show earlier glutathione recalls from two other Texas pharmacies, posted August 5 and September 13 [V].

The California Board of Pharmacy's copy of the Greenwich notice adds two details FDA's page lacks: the recall was started because an ingredient was labeled supplement grade, and each recalled lot reportedly passed endotoxin testing before release [V].

What people get wrong

What people get wrong

"Glutathione is being recalled." Not the whole category. The notices cover named lots from named pharmacies.

"If it was compounded, FDA checked it." FDA's own recall page says it doesn't endorse the product or company. Glutathione appears on FDA's 503A Category 1 list (updated May 14, 2026), and that list describes an enforcement posture, not approval [V]. Our categories explainer has the details.

"A passed test settles it." According to the California copy, these lots passed endotoxin testing and were recalled anyway [V].

What we know, and what we can't confirm

Confirmed in primary documents: the company, the date, the stated reason, the distribution window and the two emergency-care reports [V].

Not confirmed: [U] whether these lots used the same ingredient lot FDA described in August; [U] why the lot lists differ between FDA's page and the California copy; [U] how many people received them, or whether more reports have come in since October 1. FDA's recall list, current as of October 21, shows the entry with no "terminated" mark, which FDA says means ongoing or completed [V].

Why this matters to you

A recall like this turns on two facts printed on a label: who made it and which lot. That's why the questions below start there.

Questions to bring to a clinician or pharmacist

  1. Who prepared this product, and is it on any current recall notice?
  2. Was it made with ingredients intended for injection?
  3. How would I know which lot I received?
  4. Whom do I contact, and where do I report a problem, if something seems off?

Questions, not advice: someone who knows your health history can say what applies to you.

What to watch next

FDA said on August 27 it would "provide updates as additional information becomes available" [V], and we haven't seen one for Greenwich since October 1. For the bigger picture of compounded drugs, see our approved vs. wellness-market comparison and the telehealth post.

Sources (all retrieved October 25, 2026)

  1. FDA, Greenwich Rx recall announcement, Oct 1, 2026 (content current 10/01/2026) [V]: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/greenwich-rx-issues-voluntary-nationwide-recall-compounded-glutathione-due-elevated-endotoxin-levels
  2. FDA MedWatch bulletin, Oct 2, 2026 [V]: https://content.govdelivery.com/accounts/USFDA/bulletins/42d7f3c
  3. California Board of Pharmacy recall alert, file name dated 100126; the text itself carries no date [V]: https://pharmacy.ca.gov/about/recall_alerts/100126_greenwich.pdf
  4. FDA, "FDA reminds compounders not to use dietary supplement grade glutathione for injectables," Aug 27, 2026 [V]: https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
  5. CDC, injectable glutathione current situation, Sept 15, 2026 [V]: https://www.cdc.gov/healthcare-associated-infections/current-situation/index.html
  6. FDA, Drug Recalls list, current as of 10/21/2026 [V]: https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls
  7. FDA, 503A Category 1 list, updated May 14, 2026 [V]: https://www.fda.gov/media/94155/download
  8. FDA, Centric Compounding recall announcement, published Sept 13, 2026 [V]: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/centric-compounding-issues-nationwide-recall-glutathione-myers-cocktail-and-tri-immune-boost-due
  9. FDA, Victory Medical Center Pharmacy recall announcement, Aug 5, 2026 [V]: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/victory-medical-center-pharmacy-issues-voluntary-nationwide-recall-certain-lots-compounded

Reading this for health reasons? This site reports on regulation; it is not medical advice. See our disclaimer, how we source and corrections policy.

Image: AI-generated. Image credits